Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Plasminogen activator inhibitor in the blood of patients with coronary artery disease.

× No keyword cloud information.

4 in total

1. Fibrinolytic activity and coronary-artery disease.

Authors: R Chakrabarti; E D Hocking; G R Fearnley; R D Mann; T N Attwell; D Jackson
Journal: Lancet Date: 1968-05-11 Impact factor: 79.321

2. Mechanisms of inhibition of tissue-type plasminogen activator in blood.

Authors: D Collen
Journal: Thromb Haemost Date: 1983-10-31 Impact factor: 5.249

3. Plasma levels of a specific inhibitor of tissue-type plasminogen activator (and urokinase) in normal and pathological conditions.

Authors: I Juhan-Vague; B Moerman; F De Cock; M F Aillaud; D Collen
Journal: Thromb Res Date: 1984-03-01 Impact factor: 3.944

4. Generation in plasma of a fast-acting inhibitor of plasminogen activator in response to endotoxin stimulation.

Authors: M Colucci; J A Paramo; D Collen
Journal: J Clin Invest Date: 1985-03 Impact factor: 14.808

4 in total

27 in total

1. Effects of doxazosin and atenolol on the fibrinolytic system in patients with hypertension and elevated serum cholesterol.

Authors: J H Jansson; B Johansson; K Boman; T K Nilsson
Journal: Eur J Clin Pharmacol Date: 1991 Impact factor: 2.953

Review 2. Vessel wall-related risk factors in acute vascular events.

Authors: L Badimon; J J Badimon; M Cohen; J H Chesebro; V Fuster
Journal: Drugs Date: 1991 Impact factor: 9.546

3. Metabolic and haemostatic effects of estradiol valerate/dienogest, a novel oral contraceptive: a randomized, open-label, single-centre study.

Authors: Wolfgang Junge; Uwe Mellinger; Susanne Parke; Marco Serrani
Journal: Clin Drug Investig Date: 2011 Impact factor: 2.859

4. A Common Calibrator Does Not Secure Harmonisation of Commercial t-PA and PAI-1 Antigen Measurements.

Authors: Moniek P M de Maat; Jorgen Gram; Jorgen Jespersen; Cornelis Kluft
Journal: EJIFCC Date: 2001-07-22

5. Immunohistochemical localization of plasminogen activator inhibitor-1 in human coronary atherosclerotic lesions involved in acute myocardial infarction.

Authors: K Yorimitsu; T Saito; T Toyozaki; T Ishide; N Ohnuma; Y Inagaki
Journal: Heart Vessels Date: 1993 Impact factor: 2.037

6. Enalapril related changes in the fibrinolytic system in survivors of myocardial infarction.

Authors: J H Jansson; K Boman; T K Nilsson
Journal: Eur J Clin Pharmacol Date: 1993 Impact factor: 2.953

7. Plasminogen activator inhibitor activity and other fibrinolytic variables in patients with coronary artery disease.

Authors: J Aznar; A Estellés; G Tormo; P Sapena; V Tormo; S Blanch; F España
Journal: Br Heart J Date: 1988-05

8. Circadian variation of tissue plasminogen activator and its inhibitor, von Willebrand factor antigen, and prostacyclin stimulating factor in men with ischaemic heart disease.

Authors: A B Bridges; M McLaren; N A Scott; T H Pringle; G P McNeill; J J Belch
Journal: Br Heart J Date: 1993-02

Review 9. Physical activity and lipoprotein lipid disorders.

Authors: A Berg; I Frey; M W Baumstark; M Halle; J Keul
Journal: Sports Med Date: 1994-01 Impact factor: 11.136

10. Plasminogen activator inhibitor-1 gene-deficient mice. II. Effects on hemostasis, thrombosis, and thrombolysis.

Authors: P Carmeliet; J M Stassen; L Schoonjans; B Ream; J J van den Oord; M De Mol; R C Mulligan; D Collen
Journal: J Clin Invest Date: 1993-12 Impact factor: 14.808